Elderly Slide 2.png

Applying breakthrough science to develop life-saving vaccines for people in need around the globe

A next-generation, broad-coverage pneumococcal disease vaccine 

Despite a number of commercially available vaccines,
Streptococcus pneumoniae infections are still responsible for more than 1,000,000 deaths worldwide per year!


We are developing a next-generation, recombinant protein vaccine to profoundly reduce the devastating global impact of pneumococcal disease.

Streptococcus Pneumoniae.png

Streptococcus pneumoniae

CDifficile.png

Clostridiodes difficile

A novel C. difficile vaccine that targets the bacteria and the toxins

Clostridiodes difficile, classified by the US Centers for Disease Control and Prevention (CDC) as an urgent public health threat, is estimated to cause half a million infections per annum in the US alone. 


We are developing a novel, triple antigen C. difficile vaccine that targets the bacteria and the toxins, reducing bacterial colonization and preventing toxicity.